View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 5, 2019updated 12 Jul 2022 1:05pm

Amgen reports preliminary results from KRAS inhibitor trial

Amgen has reported initial data from a Phase I clinical trial assessing an investigational KRASG12C inhibitor for the treatment of solid tumours.

Amgen has reported initial data from a Phase I clinical trial assessing an investigational KRASG12C inhibitor for the treatment of solid tumours.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Called AMG 510, the therapeutic did not show any dose-limiting toxicity and demonstrated anti-tumour activity when given as a monotherapy to patients with locally advanced or metastatic KRASG12C mutant solid tumours.

KRAS is an oncogene that has limited druggability due to its lack of traditional small molecule binding pockets on the protein. It is found in multiple tumour types, including those associated with lung and colorectal cancers.

Amgen research and development (R&D) executive vice-president David Reese said: “AMG 510 seeks to crack the KRAS code by exploiting a previously hidden groove on the protein surface. By irreversibly binding to cysteine 12 on the mutated KRAS protein, AMG 510 is designed to lock it into an inactive state.

“With high selectivity for KRASG12C, we believe investigational AMG 510 has high potential as both a monotherapy and in combination with other targeted and immune therapies.”

The first-in-human, open-label, multi-centre Phase I clinical trial evaluated 180mg, 360mg, 720mg and 960mg doses of the drug candidate in a total of 35 patients.

Of the total subjects, 14 had non-small cell lung cancer (NSCLC) and 19 had colorectal cancer (CRC). Participants were pretreated with at least two or more lines of therapy.

The primary endpoint of the trial was drug safety, while key secondary endpoints included pharmacokinetics (PK), objective response rate (ORR), duration of response and progression-free survival (PFS).

According to the results, five out of ten evaluable NSCLC patients achieved a partial response (PR) and four had stable disease (SD), demonstrating a disease control rate (DCR) of 90%.

All five patients that experienced a response had therapy duration of 7.3-27.4 weeks at data cutoff. One patient with partial response improved to a complete response at week 18, which is post data cutoff.

Investigators reported that 13 of 18 evaluable subjects with CRC achieved stable disease. Of the total patients, 26 remain in the trial and nine have discontinued.

During the trial, treatment-related adverse events (AE) were primarily grade 1 events, with grade 3 drug-related AEs being anaemia and diarrhoea.

The data did not show any grade 4 treatment-related AEs or serious treatment-related AEs.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena